VTRS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

3.50B

-0.75%

0.533

-1.21%

3.31B

+1.76%

0.554

+10.8%

3.63B

+1.28%

0.637

+2.7%

Estimates Revision

The market is revising Upward the revenue expectations for Viatris Inc. (VTRS) for FY2025, with the revenue forecasts being adjusted by 1.29% over the past three months. During the same period, the stock price has changed by 31.01%.

Revenue Estimates for FY2025

Revise Upward

+1.29%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.13%

In Past 3 Month

Stock Price

Go Up

+31.01%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast VTRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTRS is 11.00 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

3 Hold

1 Sell

Hold

Current: 0.000

Low

9.00

Averages

11.00

High

14.00

Current: 0.000

Low

9.00

Averages

11.00

High

14.00

Truist

Les Sulewski

Buy

maintain

$15 -> $16

2026-01-07

New

Reason

Truist

Les Sulewski

Price Target

$15 -> $16

2026-01-07

New

maintain

Buy

Reason

Truist analyst Les Sulewski raised the firm's price target on Viatris to $16 from $15 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into 2026, the analyst tells investors in a research note.

Wedbush

Laura Chico

Neutral

maintain

$23 -> $33

2025-12-11

Reason

Wedbush

Laura Chico

Price Target

$23 -> $33

2025-12-11

maintain

Neutral

Reason

Wedbush analyst Laura Chico raised the firm's price target on Vera Therapeutics to $33 from $23 and keeps a Neutral rating on the shares. The firm notes the company completed an upsized $261M secondary offering. The deal included issuance of 6.1M shares of common stock at $42.50/share. The offering also incorporated an overallotment of 921k additional shares. Assuming exercise of the shoe, Wedbush estimates the offering will generate $281M in net proceeds. The firm's prior estimates assumed a later offering of similar magnitude.

Evercore ISI

Gavin Clark-Gartner

Outperform

maintain

$75 -> $97

2025-12-08

Reason

Evercore ISI

Gavin Clark-Gartner

Price Target

$75 -> $97

2025-12-08

maintain

Outperform

Reason

Evercore ISI analyst Gavin Clark-Gartner raised the firm's price target on Vera Therapeutics to $97 from $75 and keeps an Outperform rating on the shares. Voyxact's pricing at $30,000 per vial, totaling $390,000 annually, exceeds investor expectations and the firm's updated IgAN market model now forecasts $12.5B in peak worldwide sales, with $9.4B from the U.S. alone, the analyst says.

Barclays

Glen Santangelo

Overweight

initiated

$15

2025-12-08

Reason

Barclays

Glen Santangelo

Price Target

$15

2025-12-08

initiated

Overweight

Reason

Barclays analyst Glen Santangelo initiated coverage of Viatris with an Overweight rating and $15 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."

Truist

Buy

initiated

$15

2025-10-15

Reason

Truist

Price Target

$15

2025-10-15

initiated

Buy

Reason

Truist initiated coverage of Viatris with a Buy rating and $15 price target. While acknowledging that legacy Viatris concerns are "still prevalent across the franchise," the firm sees "an affirmative change" in the direction of the company under a refreshed leadership team, supported by a market leading branded portfolio, a progressive generics foothold, and "a robust pipeline with blockbuster potential," the analyst tells investors. Upside could come from an earlier than anticipated return to full operations at the Indore manufacturing facility and pipeline "overdelivery," the analyst added.

Goldman Sachs

Neutral

initiated

$10

2025-06-06

Reason

Goldman Sachs

Price Target

$10

2025-06-06

initiated

Neutral

Reason

Goldman Sachs initiated coverage of Viatris with a Neutral rating and $10 price target. The firm awaits clarity on the company's growth outlook given current structural dynamics in the core business and believes consensus estimates appear fair. On the generics side, it expects modest growth as Goldman monitors Viatris' ability to more meaningfully off-set legacy product erosion via new product launches and portfolio optimization.

Valuation Metrics

The current forward P/E ratio for Viatris Inc (VTRS.O) is 5.22, compared to its 5-year average forward P/E of 3.91. For a more detailed relative valuation and DCF analysis to assess Viatris Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

3.91

Current PE

5.22

Overvalued PE

4.51

Undervalued PE

3.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

6.18

Current EV/EBITDA

6.74

Overvalued EV/EBITDA

6.61

Undervalued EV/EBITDA

5.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.88

Current PS

1.01

Overvalued PS

1.00

Undervalued PS

0.75

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 247.32% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

VTRS News & Events

Events Timeline

No data

News

5.0

01-08PRnewswire

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

5.0

01-08Newsfilter

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

3.5

2025-12-18PRnewswire

Viatris Secures FDA Approvals for Four New Drugs, Advancing R&D Progress

People Also Watch

Frequently Asked Questions

What is Viatris Inc (VTRS) stock price today?

The current price of VTRS is 12.76 USD — it has increased 1.27 % in the last trading day.

What is Viatris Inc (VTRS)'s business?

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.

What is the price predicton of VTRS Stock?

What is Viatris Inc (VTRS)'s revenue for the last quarter?

Viatris Inc revenue for the last quarter amounts to 3.76B USD, increased 0.23 % YoY.

What is Viatris Inc (VTRS)'s earnings per share (EPS) for the last quarter?

Viatris Inc. EPS for the last quarter amounts to -0.11 USD, decreased -237.50 % YoY.

What changes have occurred in the market's expectations for Viatris Inc (VTRS)'s fundamentals?

How many employees does Viatris Inc (VTRS). have?

Viatris Inc (VTRS) has 32000 emplpoyees as of January 10 2026.

What is Viatris Inc (VTRS) market cap?

Today VTRS has the market capitalization of 14.70B USD.